After touting Gazyva's potential in lupus, Roche nabs 'breakthrough' ahead of PhIII
Roche’s effort to introduce its blood cancer drug Gazyva to the immunology space just got a boost from the FDA.
Regulators have granted breakthrough designation to the use of the CD20-targeting antibody in lupus nephritis, a life-threatening manifestation of systemic lupus erythematosus in the kidney. Up to 60% of all people with lupus — disproportionately women — develop such inflammation in the kidney, the Lupus Foundation of America estimates.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.